These changes resulted in the modulation of the effector function of CD4+ T cells and differential disease susceptibility in experimental inflammatory skin diseases in the mice, namely antibody-transfer autoimmune skin blistering disease epidermolysis bullosa acquisita (EBA) and imiquimod (IMQ)-induced psoriasiform dermatitis. The gene discussed is CD4; the disease is acquired epidermolysis bullosa.